Savara Inc. (NasdaqGS: SVRA)
Health Care · Biotechnology · US
$4.83
-1.02% today · +39.2% 1Y
Savara Inc. (NasdaqGS: SVRA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.23B and employs 70 people.
Over the last twelve months the share price has gained 39.2%, trading between 3.34 and 7.01.
Tweenvest scores Savara Inc. across four factors: quality 36/100, value 61/100. Its strongest factor is value.
SVRA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.23B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.58
- Dividend yield
- —
- Beta (5Y)
- 0.20
- 52-week high
- $7.01
- 52-week low
- $3.34
- Avg volume (3M)
- —
- Shares outstanding
- 254.14M
- Employees
- 70
- Next earnings
- —
About Savara Inc.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
- ISIN
- US8051111016
- Founded
- 2007
- Listed since
- Apr 28, 2017
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Nanjing Leads Biolabs Co., Ltd.SEHK: 9887 | $1.25B | HK$50.45 | -3.54% |
| Seegene, Inc.KOSDAQ: A096530 | $1.25B | ₩36,900.00 | +8.53% |
| HOB Biotech Group Corp.,LtdSHSE: 688656 | $1.23B | CN¥131.72 | -0.33% |
| Replimune Group, Inc.NasdaqGS: REPL | $1.23B | $13.04 | -0.23% |
| MannKind CorporationNasdaqGM: MNKD | $1.22B | $3.42 | -10.00% |
| Amoy Diagnostics Co., Ltd.SZSE: 300685 | $1.21B | CN¥21.34 | +2.55% |
| Daan Gene Co., Ltd.SZSE: 002030 | $1.20B | CN¥5.75 | +1.41% |
| Aimed Bio Inc.KOSDAQ: A0009K0 | $1.19B | ₩24,800.00 | +15.89% |
Figures last refreshed Oct 4, 2026.